IBRX (Immunitybio, Inc.) — AI Stock Analysis & Recommendation

Research of October 9, 2026 · Healthcare / Biological Products, (No Diagnostic Substances)

TradeFlare's AI research teams rate IBRX a HOLD. The latest price is $9.80.

The research plan

• Entry: $10.51
• Target: $12.36
• Stop: $8.93
• Time horizon: weeks

The post-earnings drift signal suggests a short-to-medium term upward move, but the high risk and neutral technicals warrant caution.

Why

The post-earnings drift signal suggests a short-to-medium term upward move, but the high risk and neutral technicals warrant caution. Catalysts to watch: Continued positive momentum from ANKTIVA's oncology performance; Potential for further positive news or analyst upgrades; The post-earnings drift signal itself is a short-term catalyst. Key risks: High product concentration risk on ANKTIVA; Significant cash burn and potential for future dilution; High volatility and beta, making the stock susceptible to market swings.

What could push IBRX higher

• Continued positive momentum from ANKTIVA's oncology performance.
• Potential for further positive news or analyst upgrades.
• The post-earnings drift signal itself is a short-term catalyst.

Key risks for IBRX

• High product concentration risk on ANKTIVA.
• Significant cash burn and potential for future dilution.
• High volatility and beta, making the stock susceptible to market swings.

What each AI research team found

Fundamental team: Neutral · valuation: speculative

ImmunityBio presents a speculative growth story with strong revenue and gross margins, but faces significant financial headwinds from its substantial cash burn and negative equity. The high insider ownership and positive analyst sentiment offer some support, but the path to profitability remains uncertain, making it a neutral call with a target aligned with analyst consensus.

• ImmunityBio exhibits strong revenue growth (93.9% YoY) driven by its approved product ANKTIVA, which boasts exceptionally high gross margins (99.34%).
• Despite revenue momentum, the company is pre-profitability with significant net losses and a substantial operating cash burn (-$141.85M in the latest quarter), leading to negative equity and a short cash runway.
• Valuation is highly speculative, reflected in a high Price-to-Sales (P/S) TTM multiple of 67.19 and negative forward P/E, driven by pipeline potential rather than current earnings.

Technical team: Neutral

The analysis presents a mixed picture with conflicting signals. While Pattern Recognition indicates bullish potential, the Trend and Volume analyses suggest a neutral to sideways consolidation. Momentum is also mixed, offering no clear directional bias. Therefore, a neutral verdict is warranted until clearer signals emerge.

• Price is consolidating near the MA50, with potential for an upward move towards resistance if the MA20 crosses above the MA50 and breaks above current resistance.
• The stock is trading sideways with volume generally below average, suggesting a neutral outlook until a clear trend emerges with strong volume confirmation.
• The stock is trading near resistance with mixed signals from momentum indicators, suggesting a neutral outlook with potential for a breakout or pullback.

Sentiment team: Bullish

IBRX exhibits strong positive sentiment across news and social media, primarily driven by the promising ANKTIVA drug and its international approvals. While professional analyst sentiment is positive, its low confidence score indicates limited coverage, but the overall trend is improving, supported by retail conviction and institutional buying.

• ImmunoBio (IBRX) news sentiment is predominantly positive, driven by strong rallies fueled by ANKTIVA's oncology momentum and recent regulatory approvals, despite some insider selling concerns. (Score: 0.15)
• Retail investor sentiment for IBRX is overwhelmingly positive, driven by strong conviction in the potential of its lead drug ANKTIVA and anticipation of regulatory catalysts, despite some concerns regarding the US approval process and financial...
• IBRX exhibits a positive sentiment driven by strong analyst buy ratings, institutional accumulation, and positive news regarding its oncology drug Anktiva, despite some insider selling and negative near-term EPS estimates.

Risk team: High

IBRX presents a high-risk profile due to its extreme volatility, product concentration, and reliance on binary clinical and regulatory outcomes. The significant historical drawdowns and high short interest amplify these risks, necessitating a very cautious approach. A small position size with strict risk management is recommended.

• Product Concentration and Clinical Trial Outcome Risk: IBRX's heavy reliance on ANKTIVA makes it highly vulnerable to clinical trial failures and regulatory setbacks, which are binary events for pre-revenue biotechs.
• High Beta and Extreme Volatility: The stock exhibits high beta and significant realized volatility, indicating amplified systematic risk and potential for extreme price swings, exacerbated by high short interest.
• Cash Burn and Dilution Risk: Ongoing cash burn necessitates potential future financing, carrying a substantial risk of shareholder dilution, especially before key catalysts, despite a seemingly strong current ratio.

IBRX at a glance

Market value	$10.3B
Profit margin	-598.6%
Debt / equity	-0.08

TradeFlare's published calls on IBRX

• January 19, 2026: reached target, +35.5%

Every AI call on IBRX since August 28, 2026, and what happened next (4 calls) →

Research of October 9, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.